Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape.

Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape.

Publication date: Jul 23, 2024

Papain-like protease (PLpro) is an attractive drug target for SARS-CoV-2 because it is essential for viral replication, cleaving viral poly-proteins pp1a and pp1ab, and has de-ubiquitylation and de-ISGylation activities, affecting innate immune responses. We employ Deep Mutational Scanning to evaluate the mutational effects on PLpro enzymatic activity and protein stability in mammalian cells. We confirm features of the active site and identify mutations in neighboring residues that alter activity. We characterize residues responsible for substrate binding and demonstrate that although residues in the blocking loop are remarkably tolerant to mutation, blocking loop flexibility is important for function. We additionally find a connected network of mutations affecting activity that extends far from the active site. We leverage our library to identify drug-escape variants to a common PLpro inhibitor scaffold and predict that plasticity in both the S4 pocket and blocking loop sequence should be considered during the drug design process.

Open Access PDF

Concepts Keywords
Attractive Antiviral Agents
Drug Antiviral Agents
Genes Catalytic Domain
Library Coronavirus 3C Proteases
Viral Coronavirus 3C Proteases
Coronavirus Papain-Like Proteases
Coronavirus Papain-Like Proteases
COVID-19
COVID-19 Drug Treatment
HEK293 Cells
Humans
Models, Molecular
Mutation
papain-like protease, SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
drug DRUGBANK Papain
pathway KEGG Viral replication
disease IDO site
disease IDO process
disease MESH COVID 19
disease MESH death
disease VO population
drug DRUGBANK Esomeprazole
disease VO effective
disease IDO host
drug DRUGBANK L-Lysine
drug DRUGBANK L-Arginine
drug DRUGBANK L-Leucine
drug DRUGBANK Indole
pathway REACTOME Metabolism
disease IDO assay
disease IDO cell
pathway KEGG Ribosome
drug DRUGBANK Puromycin
drug DRUGBANK Zinc
disease VO dose
drug DRUGBANK Succimer
drug DRUGBANK Doxycycline
disease MESH infection
disease MESH premature stop codons
drug DRUGBANK Histidine
disease VO frequency
disease MESH defects
drug DRUGBANK Flunarizine
drug DRUGBANK Trestolone
disease VO viability
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Protein C
drug DRUGBANK Cysteamine
disease VO efficiency
disease IDO quality
drug DRUGBANK L-Tryptophan
drug DRUGBANK Alpha-Linolenic Acid
drug DRUGBANK Methionine
drug DRUGBANK L-Cysteine
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK L-Asparagine
drug DRUGBANK L-Tyrosine
drug DRUGBANK Glycine
drug DRUGBANK Serine
disease VO manufacturer
disease VO Lentivirus
drug DRUGBANK L-Glutamine
disease IDO production
disease VO Gag
drug DRUGBANK Calcium Phosphate
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Nitrogen
disease IDO facility
drug DRUGBANK Kanamycin
drug DRUGBANK Aspartame
drug DRUGBANK Huperzine B
drug DRUGBANK Trimebutine
disease IDO replication
disease VO time
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
drug DRUGBANK Tromethamine
drug DRUGBANK Imidazole
drug DRUGBANK Lysozyme
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Acetate ion
drug DRUGBANK Human Serum Albumin
disease VO volume
drug DRUGBANK Glutathione
drug DRUGBANK Sodium Citrate
drug DRUGBANK Glycerin
drug DRUGBANK Water
drug DRUGBANK Gold
disease IDO pathogen
disease VO Enterovirus
disease VO efficient
disease MESH tumor
pathway KEGG Necroptosis
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)